Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia
Open Access
Abstract
Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene mutations are the most common genetic abnormality in AML, detectable in blast cells from about one-third of adults with AML. AML NPM1mut is recognized as a separate entity in the World Health Organization classification of AML. Clinical and survival data suggest that patients with this form of AML often have a more favorable prognosis, which may be due to the immunogenicity created by the mutations in the NPM1 protein. Consequently, AML with NPM1mut can be considered an immunogenic subtype of AML. However, the underlying mechanisms of this immunogenicity and associated favorable survival outcomes need to be further investigated. Immune checkpoint molecules, such as the programmed cell death-1 (PD-1) protein and its ligand, PD-L1, play important roles in leukemogenesis through their maintenance of an immunosuppressive tumor microenvironment. Preclinical trials have shown that the use of PD-1/PD-L1 checkpoint inhibitors in solid tumors and lymphoma work best in novel therapy combinations. Patients with AML NPM1mut may be better suited to immunogenic strategies that are based on the inhibition of the PD-1 immune checkpoint pathway than patients without this mutation, suggesting the genetic landscape of patients may also inform best practice for the use of PD-1 inhibitors.Keywords
All Related Versions
This publication has 110 references indexed in Scilit:
- Targeting the undruggable: menin inhibitors ante portasJournal of Cancer Research and Clinical Oncology, 2023
- Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatmentAmerican Journal of Hematology, 2022
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachCancer, 2021
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerJAMA Oncology, 2020
- WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesAmerican Journal of Hematology, 2015
- Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaCancer, 2013
- Assay of human stem cells by repopulation of NOD/SCID miceStem Cells, 1997
- Major nucleolar proteins shuttle between nucleus and cytoplasmCell, 1989
- Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cellsPharmacology & Therapeutics, 1985